3651 results for «235»
3651 results
Haemodynamic support: from shock to complex high-risk interventional problems
21 May 2026 – From EuroPCR 2026
This session examines haemodynamic support from cardiogenic shock through to complex high-risk interventional cardiology procedures. It features registry data, clinical outcomes, and procedural techniques including mechanical circulatory support and arterial access strategies.
Inflammation and cardiovascular risk
21 May 2026 – From EuroPCR 2026
Exploring the interplay between inflammation and cardiovascular risk, this session reviews contemporary research on residual risk post-PCI, inflammatory markers in coronary artery disease especially in type 2 diabetes and ACS, and prognostic tools including lipoprotein(a) and systemic inflammation indices.
Left main PCI, what is known and what is new
21 May 2026 – From EuroPCR 2026
This session examines both established knowledge and novel advances in left main PCI. Topics include the use of novel stents and laser atherectomy in calcified lesions, the prognostic impact of cardiac motion during bifurcation PCI, effects of left ventricular dysfunction, and sex-specific survival outcomes, as well...
Modern risk prediction in TAVI
21 May 2026 – From EuroPCR 2026
This session examines modern risk prediction models in transcatheter aortic valve implantation (TAVI). It presents novel scoring systems, the prognostic significance of cardiac damage extent and progression, and the impact of multivalvular disease, enhancing patient stratification and outcome prediction.
Combined mitral repair and LAA closure with two separate septal punctures - LIVE case
21 May 2026 – From EuroPCR 2026
A 79‑year‑old man with hypertension, a history of basal cell carcinoma and psoriasis, presented with symptomatic severe primary MR (flail P2 due to ruptured chordae) and bleeding complications (recurrent skin bleeding) while on DOAC therapy for permanent atrial fibrillation.
Two G5 MitraClip devices were implanted. Subsequently, through...
PCI of calcified distal left main stenosis - LIVE case
19 May 2026 – From EuroPCR 2026
A 54‑year‑old man with hypertension, smoking, dyslipidemia, and a history of PCI to the OM and diagonal branches in 2004 presented with a significant calcified LM–LAD stenosis.
The proximal LAD lesion was prepared with IVL followed by implantation of a 3.5 × 28 mm stent. The left...
BYPASS-CTCA: The value of computed tomography cardiac angiography in improving patient satisfaction and reducing contrast load, procedural duration and complications in patients who had previous CABG undergoing invasive coronary angiography
19 Sep 2022
Nicola Ryan provides her take on the BYPASS-CTCA Study which was presented by Daniel A. Jones at the TCT Congress 2022.
It must be understood that the paper has yet to be published for this study therefore all assumptions are based upon the presented data.
Author
EuroPCR 2026 – Long-term mortality following revascularisation for left main disease
20 May 2026
Paris, France, 19−22 May 2026. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during EuroPCR 2026 and are set to impact practice worldwide. Among them is a meta-analysis of long-term data from 4 randomised trials investigating...
FFR or 3d-quantitative coronary angiography-based vessel-FFR guided revascularisation – The FAST III trial
28 Mar 2026
Chiara De Biase provides her take on the FAST III Trial presented by Joost Daemen at ACC.26 in New Orleans. She reviews the comparison between vFFR and FFR, highlighting key findings and their impact on revascularisation strategies.
Author
Impact of intravascular imaging guidance on percutaneous coronary intervention of severely calcified lesions: The ECLIPSE trial
29 Mar 2025
Aaysha Cader provides her take on the ECLIPSE trial presented by Gregg W. Stone at ACC.25 in Chicago.
Author
INFINITY-SWEDEHEART - Percutaneous coronary intervention with a bioadaptor compared to a contemporary drug eluting stent- one year primary outcomes
03 Sep 2024
Daniele Giacoppo provides his take on the main results of the INFINITY-SWEDEHEART trial presented by David Erlinge at the ESC Congress 2024 in London.
Author
